<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81915">
  <stage>Registered</stage>
  <submitdate>18/03/2007</submitdate>
  <approvaldate>26/03/2007</approvaldate>
  <actrnumber>ACTRN12607000181404</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of Memantine [N- Methyl- D- Aspartate (NMDA) receptor antagonist] versus placebo in acute non arteritic anterior ischemic optic neuropathy (NAION)</studytitle>
    <scientifictitle>In patients with NAION (Non-arteritic anterior ischemic optic neuropathy), is Memantine as good as or better than placebo for improving visual functions?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Non arteritic anterior ischemic optic neuropathy (NAION)</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>intervention: Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks) </interventions>
    <comparator>Placebo (lactose powder) for control group</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Any change in visual acuity</outcome>
      <timepoint>Baseline, then on week 3, months 3 and 6</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Any change of  VEP (visual evoked potential) parameters (amplitude and latency) and automated perimetry parameters.</outcome>
      <timepoint>From baseline with month 3.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria> Unilateral acute onset of painless visual loss, localized or generalized edema and paleness of the optic nerve head, flame shaped hemorrhages, arterial narrowing without venous congestion and RAPD (relative afferent pupillary defect) in acute phase (=8 weeks) along with visual field defect consistent with non arteritic AION in perimetry.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy and breast feeding, complete optic disc atrophy that other etiologies were suggested, presence of systemic signs and symptoms such as fever, headache consistent with arteritic AION, drug history such as anti-convulsants, barbiturates, neuroleptics, Amantadine hydrochlorothiazids and history of renal insufficiency.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>allocation concealment by contacting the holder of the allocation who was off-site</concealment>
    <sequence>allocation was concealed  by using dynamic random allocation (Minimisation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subjects, therapist or clinician, assessor, and data analyst were all masked</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/06/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Tehran University of Medical sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Ophthalmology department/ school of medicine/ Medical  Sciences/ Tehran University</fundingname>
      <fundingaddress />
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Evaluation of the neuroprotective effect of Memantine in visual function of patients with acute NAION. Our hypothesis was that Memantine helps for better improvement of visual function in acute phase of NAION</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>the investigational review board and ethics committees of Tehran University of Medical Sciences</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>214</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tehran University Eye Research Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>214</hrec>
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital
Qazvin Square
Tehran </address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Riazi-Esfahani MD</name>
      <address>Farabi Eye Hospital, Qazvin Square, Tehran </address>
      <phone>+98 9121446987</phone>
      <fax>+98 21 22678090</fax>
      <email>mriazi@sina.tums.ac.ir</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>